Hims & Hers Acquires At-Home Lab Testing Facility, Expanding Capabilities to Ultimately Include Affordable Whole Body Testing for Subscribers
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Sandler Reiterates Neutral Rating on Hims and Hers (HIMS), PT $24
February 21, 2025 12:23 PM ESTPiper Sandler analyst Korinne Wolfmeyer reiterated a Neutral rating and $24.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "We believe it's best to remain on the sidelines with HIMS following the FDA's announcement this morning that... More
Why Morgan Stanley is cautious on Hims & Hers shares
February 20, 2025 4:00 PM ESTMorgan Stanley remains cautious on Hims & Hers Health, Inc. (NYSE: HIMS) despite the companys latest move into at-home lab testing through its acquisition of Trybe Labs.
The investment bank maintains an Equal-weight rating on the stock, arguing that excitement around the companys growth potential may be outpacing realistic financial... More
Hims and Hers (HIMS) PT Raised to $21 at BofA Securities
February 20, 2025 5:18 AM ESTBofA Securities analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $21.00 (from $18.00) while maintaining a Underperform rating.
The analyst comments "HIMS observed sales per Bloomberg Second Measure (BSM) data grew 104% y/y in January and suggests GLP-1s... More
